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Background/aim: To investigate the utility of preoperative serum cancer antigen 125 (CA 125) levels in type 1 endometrial carcinoma
(EC) as a marker for determining poor prognostic factors and survival.
Material and methods: All patients with endometrial cancer, who had been treated between 2012 and 2020, were retrospectively
reviewed, and finally, 256 patients with type 1 endometrium carcinoma were included in the study. The relationship between the
clinicopathological characteristics, CA 125 level, and survival rates were analyzed. The cut-off value for the preoperative serum CA 125
level was defined as 16 IU/L.
Results: The median serum CA 125 levels were significantly higher in patients with deep myometrial invasion, lymph node metastasis,
lymphovascular space invasion, cervical stromal and adnexal involvement, advanced stage, positive peritoneal cytology, recurrence, and
adjuvant therapy requirement. Serum CA 125 cut-off values determined according to clinicopathologic factors ranged from 15.3 to 22.9
IU/L (sensitivity 61%–77%, specificity 52%–73%). The disease-specific survival rate was significantly higher in patients with CA 125
levels < 16 IU/L (P = 0.047).
Conclusion: The data showed that choosing a lower threshold value for the CA 125 level (16 IU/L) instead of 35 IU/L, could be more
useful in type 1 EC patients with negative prognostic factors.
Key words: Cancer antigen 125 (CA 125), cut-off value, endometrial carcinoma, prognosis, survival

1. Introduction
Endometrial carcinoma (EC) is the most frequent
gynecological malignancy in developed countries [1]. Most
cases are diagnosed in the early stages, and surgery remains
the mainstay of treatment. Based on histopathology and
pathological staging, patients are further classified into
low-, intermediate-, and high-risk endometrial cancer
groups [2]. These classifications help to guide clinicians
in the adjuvant chemotherapy and radiotherapy decision.
Beyond the stage and tumor histology, novel molecular
characterization can also support decision-making, but
more data are needed, and these tests are not available for
common use. Therefore, it is important to identify patients
with a high relapse rate, even before primary surgery, to
make a treatment and surveillance plan for these patients
[3].
Previous studies have shown that the level of
preoperative serum cancer antigen 125 (CA 125), which

is known as an epithelial surface tumor antigen, is a
useful marker in predicting poor prognostic factors,
such as extrauterine spread of disease and recurrence in
patients with endometrial cancer [4,5]. The CA 125 test is
widely used and accessible for patients in the gynecology
unit. Preoperative assessment of CA 125 can be used as
an additional tool in preoperative risk stratification to
delineate patients with poor outcomes [6,7]. Although
there are studies suggesting a cut-off of 35 IU/L as the
preoperative CA 125 level in determining prognostic
factors and survival in EC [4,8–11], many different cut-off
values have been used [12–19]. However, the preoperative
serum CA 125 level in endometrial cancer is still unclear
and controversial [9].
In the current study, the medical records of endometrial
cancer patients over the last 8 years were reviewed
and retrospectively analyzed to evaluate the utility of
preoperative serum CA 125 levels in type 1 EC as a marker
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for determining poor prognostic factors and survival.
2. Materials and methods
The medical records of 452 EC patients who were treated
at our tertiary gynecologic oncology center, between
February 2012 and February 2020, were analyzed. Overall,
13 patients who had undergone primary surgery at different
centers, while final surgical staging was performed in our
clinic. A total of 95 EC patients with type 2 histology, 3
patients who had synchronous endometrium and ovarian
cancer, 39 patients whose postoperative follow-up period
was less than 3 months, and 46 patients who did not have
preoperative serum CA 125 testing were excluded in the
study. Finally, 256 patients with documented preoperative
serum CA 125 levels in EC, with type 1 histology
(endometrioid and mucinous adenocarcinoma), were
included in the final analysis.
All of the patients underwent full surgical staging,
as total hysterectomy/bilateral salpingo-oophorectomy,
by the same gynecologic oncology team. Systematic
lymphadenectomy (pelvic ± para-aortic) was performed
on all of the patients, except those with grade 1–2 tumors,
with a tumor size <2 cm, and <50% myometrial invasion
(MI), according to preoperative endometrial sampling or
intraoperative frozen evaluation [20]. Moreover, based
on the experience of the surgeon, lymphadenectomy
was performed on patients with grade 2 tumors to avoid
undertreatment.
The staging was determined based on surgical and
pathological assessment according to the International
Federation of Gynecology and Obstetrics (FIGO) 2009
guidelines [21]. Adjuvant treatment decision was made
by a multidisciplinary team on a multidisciplinary tumor
board [3]. After definitive treatment, all of the patients were
followed-up once every 3 months for 2 years, once every 6
months for 2–5 years, and annual follow-up examinations
were performed each year following that.
For each patient, clinicopathological and demographic
characteristics, including preoperative serum CA 125
values, surgical procedures performed, posttreatment
findings on physical examination, imaging, and cytological
results, were investigated. Based on the histopathologic
examination results, the size of the tumor, histologic type,
grade, MI depth, peritoneal cytology, lymphovascular
space invasion (LVSI), involvement of the cervix, adnexa,
parametrium, and lymph nodes (LNs) were noted. Followup periods, presence of recurrence, disease-specific death,
overall mortality, and overall survival rates were recorded.
All preoperative serum CA 125 levels were measured by
our institutional laboratory using a chemiluminescence
microparticle immunoassay technique on an Architect
i2000 SR Immunoassay Analyzer (Abbott, Abbott Park,
IL, USA). To determine the association between the
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preoperative serum CA 125 level and prognostic factors,
the cut-off value for the CA 125 level was accepted as 16
IU/L, based on the recent literature [17,22–24].
2.1. Statistical analysis
The data were expressed as the mean ± standard deviation
or median and range for continuous variables, and binary
variables were reported as the number and percentage.
Comparison of the continuous variables between the
groups was performed using the nonparametric MannWhitney U test for all of the different clinicopathologic
factors, except the grade. The Kruskal-Wallis test was used
for comparison of the CA 125 levels in terms of the grade.
The chi square or Fisher exact tests, where applicable, were
used to determine the association of CA 125 levels with
the clinicopathologic variables (categorical variables). The
Kolmogorov-Smirnov test was used to test for normality of
the distribution.
To determine the sensitivity and specificity of the
various cut-off levels, receiver operating characteristic
(ROC) curve analysis was performed for associated factors
confirmed by logistic regression analysis. Time of follow-up
was measured from the date of diagnosis to the date of the
last visit or death. Disease-specific survival was calculated
as the number of years from the first treatment to the date
of death as the result of endometrium carcinoma, or the
last follow up date for patients who were still alive. KaplanMeier survival analysis was used to compare survival
outcomes in the CA 125 groups. P < 0.05 was accepted as
statistically significant. All analyses were performed using
SPSS Statistics for Windows 17.0 (SPSS Inc., Chicago, IL,
USA).
3. Results
The mean follow-up period was 25.5 (range: 4–93)
months. During this period, 7 patients (2.7%) died. The
overall mortality rate for the whole group was 4.7% (n
= 12). The mean age of the patients was 61 ± 9.3 years,
and 31 (12.1%) patients were <50 years of age, while 209
(81.6%) were postmenopausal. The mean body mass index
(BMI) was 34.3 ± 7.4 kg/m2 and median tumor size was
3.5 (range: 1–12) cm. The demographic characteristics of
the cohort are summarized in Table 1. While 252 patients
(98.4%) had endometrioid EC, 4 (1.6%) had mucinous EC.
The median and mean CA 125 were 16 (range: 4–1933)
IU/L and 47.8 ± 154, respectively.
The median serum CA 125 levels were significantly
higher in patients with >50% MI, LN metastasis, positive
LVSI, cervical stromal and adnexal involvement, advanced
stage, positive peritoneal cytology, recurrence, and
adjuvant therapy requirement. There was no statistical
difference in the median serum CA 125 levels for different
histologic grades and disease-specific death (Table 2). To
define the prognostic role of the serum CA 125, cut-off
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Table 1. Baseline and disease characteristics of the cohort.
Grade, n (%)
Grade 1
Grade 2
Grade 3

132 (51.6)
93 (36.3)
31 (12.1)

Stage, n (%)
Stage I
Stage II
Stage III
Stage IV

211 (82.4)
10 (3.9)
30 (11.7)
5 (2)

Type of surgery, n (%)
Laparoscopy
Laparotomy

143 (55.9)
113 (44.1)

Hysterectomy
Hysterectomy + systematic lymphadenectomy

43 (16.8)
213 (83.2)

Median number of LNs removed, n (range)
- Median number pelvic LNs
- Median number of paraaortic LNs

55 (1–164)
29 (6–65)
24 (1-94)

Adjuvant therapy, n (%)
- Radiotherapy
- Chemotherapy
- Combined therapy
* Sandwich therapy

99 (38.7)
58 (41.1)
13 (9.2)
28 (25.9)
*12 (12.1)

values were determined using ROC curve statistical tests
with clinicopathological factors. These CA 125 cut-off
values ranged from 15.3 to 22.9 IU/L (sensitivity 61%–
77%, specificity 52%–73%) (Table 3).
In agreement with this CA 125 cut-off value, the
statistical analysis showed a significant relation between
the CA 125 value and MI, advanced stage, LN metastasis,
LVSI, cervical stromal and adnexal involvement, adjuvant
therapy requirement with P = 0.023, P < 0.001, P = 0.003,
P = 0.001, P = 0.009, P = 0.001, and P = 0.003, respectively
(Table 4). On the other hand, the statistical analysis failed
to show a significant relation between the CA 125 value
and tumor grade, positive peritoneal cytology, recurrence,
and disease-specific death rate (Table 4). Patients with a
CA 125 value ≥16 IU/L had a significantly lower 5-year
disease-specific survival rate when compared to patients
with a CA 125 value <16 IU/L (95.4% vs. 98.9%, P = 0.047)
(Figure).
4. Discussion
Type 1 endometrial cancer is the most common tumor in
gynecology, which mostly presents in the early stages and
has a relatively lower rate of recurrence when compared
to type 2 endometrial cancer or uterine sarcomas. In
surgically-treated patients, an adjuvant strategy is based
on the histological type and grade, as well as tumor stage

[3]. In the current study, it was aimed to evaluate the
prognostic role of CA 125, and define cut-off values for
clinicopathologic factors. ROC-curve analysis was used
for each historical prognostic hallmark to define the
proper cut-off value for the whole group. Based on the
literature, a cut-off value of 16 IU/L was defined [17,22–
24]. When this cut-off value was used, a significant relation
was found between the CA 125 value and MI, advanced
stage, LN metastasis, LVSI, cervical stromal, and adnexal
involvement. Furthermore, it is noteworthy that the CA
125 value showed a significant effect on the 5-year diseasefree survival time. This statistically significant difference
reached an absolute difference of 3.5% (95.4 vs. 98.9%) in
the Kaplan-Meier survival analysis, which has high clinical
relevance.
In the literature, a respective number of studies have
mostly included whole histological types of endometrial
cancer and reported that elevated serum CA 125 levels might
be useful in determining poor prognostic factors, such
as extrauterine spread and LN metastasis in EC [25–27].
There have been different CA 125 cut-off values reported
in different studies [8,14,16,17]. A study that involved 757
patients, which defined age-stratified cut-off levels for
CA 125 values to improve prognostic classification in EC,
suggested that the cut-off value was 35 IU/L for patients
>49 years of age, and 105 IU/L for those <49 [8]. On the
other hand, cut-off levels of poor prognostic factors, which
were defined using the ROC curve, ranged from 16.2 to
40.8 IU/L, with 53.4%–84.2% sensitivity and 43.9%–81.7%
specificity, in the study of Kim et al. [17]. Previous studies
have also reported preoperative serum CA 125 cut-off
values in the range of 15 to 35 IU/L for poor prognostic
factors in EC [11,14,15]. Based on the current results,
the serum CA 125 cut-off values, which were determined
according to the clinicopathologic factors, ranged from
15.3 to 22.9 IU/L (sensitivity 61%–77%, specificity 52%–
73%). This study specifically consisted of patients with
type 1 EC, which may have been a possible reason for
the lower cut-off values when compared to those in the
study of Chao et al., which included all types of EC [8].
Moreover, 12.1% of the patients were <50 years of age
in the cohort herein, therefore, no further analysis was
performed for this age group. In a study that included 423
patients with endometrioid EC, elevated CA 125 levels (35
IU/L) were found to be associated with tumor spreading
and LN metastasis; however, after adjusting for age, the CA
125 cut-off to predict LN metastasis was found to be 16
IU/L in patients >50 years of age, which was similar to the
results herein [24].
Moreover, the current study demonstrated that the
median serum CA 125 levels were significantly higher in
patients with adverse clinicopathologic factors, except for
advanced grade. The studies of Kim et al. and Chung et al.
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Table 2. Median CA 125 levels based on different clinicopathologic factors.
Clinicopathologic factors

Grade

MI
(>50%)
Lymph node metastasis
LVSI
Cervical stromal invasion
Adnexal involvement
Positive peritoneal cytology
Advanced stage
(stage 3–4)
Recurrence
Adjuvant therapy requirement
Disease-specific death

N (%)

Median CA 125 level
(IU/L) (range)

1

132 (51.6)

14.5 (4–600)

2

93 (36.3)

16 (4–811.7)

3

31 (12.1)

20 (5–1933)

+

56 (22.3)

19.5 (5–788)

–

195 (77.7)

15 (4–1933)

+

22 (8.6)

31 (7–788)

–

234 (91.4)

15 (4–1933)

+

79 (30.9)

20 (4–1933)

–

177 (69.1)

13 (4–811.7)

+

20 (7.8)

20.8 (4–788)

–

236 (92.2)

15 (4–1933)

+

26 (10.4)

35 (6-1933)

–

225 (89.6)

15 (4–600)

+

9 (4)

33 (7–1933)

–

218 (96)

15 (4–600)

+

45 (17.6)

24 (4–1933)

–

211 (82.4)

15 (4–600)

+

100 (39.1)

19 (4–1933)

–

156 (60.9)

13.5 (4–600)

+

18 (7)

21.3 (7–1933)

–

238 (93)

15 (4–788)

+

7 (2.7)

19.5 (13–444)

–

249 (97.3)

15 (4–1933)

P-value

0.052

0.007
<0.001
<0.001
0.017
<0.001
0.029
<0.001
0.002
0.049
0.050

Table 3. Preoperative CA 125 cut-off values, sensitivity, specificity, AUC (95% CI) in type 1 endometrium cancer
at different clinicopathologic factors.
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Cut-off value

Sensitivity,
specificity

AUC (95%CI)

P-value

Advanced grade (grade 3)

15.8 IU/L

61%–52%

0.60 (0.49–0.71)

0.07

MI (>50%)

16.1 IU/L

61%–57%

0.62 (0.53–0.71)

0.007

Lymph node metastasis

22.9 IU/L

76%–72%

0.76 (0.65–0.87)

<0.001

LVSI

16.7 IU/L

62%–61%

0.68 (0.60–0.75)

<0.001

Cervical stromal invasion

18.7 IU/L

70%–63%

0.66 (0.53–0.80)

0.017

Adnexal involvement

18.7 IU/L

77%–64%

0.77 (0.67–0.87)

<0.001

Positive peritoneal cytology

22.9 IU/L

67%–73%

0.72 (0.50–0.93)

0.029

Advanced stage (stage 3-4)

18.7 IU/L

69%–66%

0.71 (0.61–0. 80)

<0.001

Adjuvant therapy requirement

15.3 IU/L

62%–57%

0.62 (0.54–0.69)

0.002

Recurrence

18.4 IU/L

61%–61%

0.64 (0.49–0.78)

0.049

Disease-specific death

18.4 IU/L

71%–61%

0.72 (0.57–0.87)

0.05

YILMAZ BARAN et al. / Turk J Med Sci
Table 4. Comparison of characteristics of patients with type 1 endometrial cancer with and without elevated CA 125 when
cut-off is16 IU/L.
CA 125 level < 16 IU/L, n (%)

CA 125 level ≥ 16 IU/L, n (%)

P-value

Advanced grade (grade 3)

12/124 (9.7)

19/126 (15.1)

0.25

MI (>50%)

20/124 (16.1)

36/127 (28.3)

0.023

Lymph node metastasis

3/99 (3)

18/121 (14.9)

0.003

LVSI

26/127 (20.5)

53/129 (41.1)

0.001

Cervical stromal invasion

4/127 (3.1)

16/129 (12.4)

0.009

Adnexal involvement

5/124 (4)

21/127 (14.8)

0.001

Positive peritoneal cytology

2/115 (1.7)

7/112 (6.3)

0.09

Advanced stage (stage 3–4)

11/127 (8.7)

34/129 (25.3)

<0.001

Adjuvant therapy requirement

38/127 (29.9)

62/129 (47.3)

0.003

Recurrence

6/127 (4.7)

12/129 (9.3)

0.22

Disease-specific death

1/127 (0.8)

6/129 (4.7)

0.12

Figure. Disease-specific survival of the type 1 endometrial cancer patients with and
without elevated CA 125 when cut-off is16 IU/L.

did not find a relationship between higher CA 125 levels
and grade, similar to the current results [14,17]. There
was no statistical difference in the median serum CA 125
levels for disease-specific death. However, the median

follow-up in the current study was 25.5 months, while the
mortality rate related to the disease was 7/256 (2.7%), and
these results may differ as the follow-up period increases.
The results of the present study demonstrated that deep
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MI, LN metastasis, LVSI, cervical stromal invasion, adnexal
involvement, advanced stage, and adjuvant treatment
requirements were higher in patients with a CA 125 level
≥16 IU/L than in those with a CA 125 level <16 IU/L,
which indicated a lower cut-off value (16 IU/L), instead
of the conventional 35 IU/L cut-off in preoperative CA
125 testing. Moreover, defining the preoperative CA 125
cut-off value as 16 IU/L provided higher rates of diseasespecific survival in the group with a CA level 125 <16 IU/L.
However, it was shown that the preoperative serum CA
125 levels themselves were not sufficient to predict positive
peritoneal cytology, recurrence, and disease-specific death;
therefore, additional diagnostic methods, such as imaging
studies, are required for preoperative counseling of patients
with EC.
Routine intraoperative frozen evaluation has been
performed to decide systematic lymphadenectomy in
patients with a grade 1–2 tumor, tumor size <2 cm, and MI
<50% in recent years. Moreover, no strict criteria have been
assigned in grade 2 EC cases. Actually, the definitions of
patients at low- and high-risk were derived from the findings
of final pathologic examinations. DiSaia and Creasman
supported the staging of all grade 2 lesions, whether
invasion was present or not [28]. On the contrary, Cochrane
found no evidence that lymphadenectomy decreased the
risk of death or disease recurrence when compared with not
having a lymphadenectomy in women with presumed stage
I disease [29]. However, it is known that 15% of histologic
grade 2 tumors are reported as grade 3 tumors in final
pathology [30]. Hence, there is still a discrepancy between

the clinical guidelines and the actual practice adopted by
clinicians regarding the role of lymphadenectomy in EC.
In this context, based on the experience of the surgeon,
lymphadenectomy was performed on patients with grade 2
tumors to avoid undertreatment in our department.
The current study had some limitations, such as its
retrospective design and selection bias. Moreover, patients
without preoperative CA 125 levels were not included.
However, the fact that only type 1 EC was included in this
study allowed it to be specific. Additionally, the standard
procedures performed by the same team and maintaining
the follow-ups of patients with a multidisciplinary approach
were the advantages of the study.
5. Conclusion
The data showed that choosing a lower threshold value for
the CA 125 level (16 IU/L), instead of 35 IU/L, could be
more useful in type 1 EC patients with negative prognostic
factors. Therefore, preoperative serum CA 125 testing
should be integrated into routine preoperative evaluation
of EC. However, further studies are needed to identify the
optimal cut-off level of CA 125.
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